6-K - GSK plc (0001131399) (Filer)
SEC · EDGAR 财务披露 · November 6, 2026 at 10:08 AM ET
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2026
Commission File Number 001-15170
GSK plc
(Translation of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc
GSK publishes provisional dividend dates
GSK announces the following dividend dates for 2027:
These dates are indicative and may be subject to change.
|
Results |
Announcement date |
Ordinary Shares Ex-dividend date |
American Depositary Shares Ex-dividend date |
Record date |
Last date for DRIP elections |
Payable |
|
Q1 2027 |
Wednesday 28 April 2027 |
Thursday 13 May 2027 |
Friday 14 May 2027 |
Friday 14 May 2027 |
Thursday 24 June 2027 |
Thursday 15 July 2027 |
|
Q2 2027 |
Wednesday 28 July 2027 |
Thursday 12 August 2027 |
Friday 13 August 2027 |
Friday 13 August 2027 |
Thursday 23 September 2027 |
Thursday 14 October 2027 |
|
Q3 2027 |
Wednesday 27 October 2027 |
Friday 12 November 2027 |
Friday 12 November 2027 |
Friday 12 November 2027 |
Monday 20 December 2027 |
Thursday 13 January 2028 |
|
Q4 2027 |
Wednesday 2 February 2028 |
Friday 18 February 2028 |
Friday 18 February 2028 |
Friday 18 February 2028 |
Thursday 23 March 2028 |
Thursday 13 April 2028 |
V A Whyte
Company Secretary
6 November 2026
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
|
GSK plc |
|
|
(Registrant) |
|
|
Date: November 06, 2026 |
|
|
By:/s/ VICTORIA WHYTE -------------------------- |
|
|
Victoria Whyte |
|
|
Authorised Signatory for and on |
|
|
behalf of GSK plc |